Rosiglitazone improves aortic arginine transport, through inhibition of PKCα, in uremic rats

Merav Ingbir, Idit F. Schwartz, Alexander Shtabsky, Irina Filip, Ran Reshef, Tamara Chernichovski, Nomi Levin-Iaina, Uri Rozovski, Yoram Levo, Doron Schwartz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Peroxisome proliferator-activated receptor (PPAR) agonists were shown to inhibit atherosclerosis through augmentation of endothelial nitric oxide synthase (eNOS) activity. In addition, rosiglitazone exerts a beneficial effect in chronic renal failure (CRF). Since L-arginine transport by CAT-1 (the specific arginine transporter for eNOS) is inhibited in uremia, we aimed to explore the effect of rosiglitazone on arginine transport in CRF. Arginine uptake by aortic rings was studied in control animals, rats, 6 wk following 5/6 nephrectomy (CRF) and rats with CRF treated with rosiglitazone. The decrease of arginine transport in CRF was prevented by rosiglitazone. Immunobloting revealed that CAT-1 protein was decreased in CRF but remained unchanged following rosiglitazone administration. Protein content of the membrane fraction of PKCα and phosphorylated CAT-1 increased significantly in CRF, effects that were prevented by rosiglitazone. PKCα phosphorylation was unchanged but significantly attenuated by rosiglitazone in CRF. Ex vivo administration of phorbol-12-myristate-13-acetate to rosiglitazone-treated CRF rats significantly attenuated the effect of rosiglitazone on arginine uptake. The decrease in cGMP response to carbamyl-choline (eNOS agonist) was significantly attenuated by rosiglitazone in CRF. Western blotting and immunohistochemistry analysis revealed that protein nitration was intensified in the endothelium of CRF rats and this was attenuated by rosiglitazone. In conclusion, rosiglitazone prevents the decrease in arginine uptake in CRF through both depletion and inactivation of PKCα. These findings are associated with restoration of eNO generation and attenuation of protein nitration and therefore may serve as a novel mechanism to explain the beneficial effects of rosiglitazone on endothelial function in uremia.

Original languageEnglish
Pages (from-to)F471-F477
JournalAmerican Journal of Physiology - Renal Physiology
Issue number2
StatePublished - Aug 2008


  • Endothelial function
  • Protein nitration
  • Uremia


Dive into the research topics of 'Rosiglitazone improves aortic arginine transport, through inhibition of PKCα, in uremic rats'. Together they form a unique fingerprint.

Cite this